- Name
- PT-141
- API
- PT-141
- Dosage10mg
- Packing3 ml vial
PT‑141 represents the first in a new group of melanocortin agonist drugs under development for managing sexual dysfunction. Its mechanism of action may provide meaningful advantages in both safety and efficacy over existing therapies, since it modulates the neural circuits that govern sexual response without acting directly on the vascular system. Clinical evidence suggests that PT‑141 can help a broad spectrum of individuals with erectile dysfunction. A nasal spray formulation in development is designed to be as convenient as oral medications, more acceptable to patients than invasive treatments such as injections or intra‑urethral preparations, and appears to produce relatively rapid effects. The drug has the potential to rival, or even surpass, Viagra in popularity, as Viagra primarily enhances blood flow to the genital tissues through vascular mechanisms. For many women, however, difficulties arise more from low sexual desire than from purely physical arousal problems. In contrast, PT‑141 engages central arousal pathways in the brain and therefore seems more likely to rekindle sexual interest.